1Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol, 2002,20(18 Suppl):1S-13S.
2Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 2001,7:2958-2970.
3Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer, 2001,37( Suppl 4):S16-S22.
4Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 2001,7:1459-1465.
5Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003,21:2237-2246.
6Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol, 2004,22:785-794.
7Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs, 2002,11:837-849.
8Sewell JM, Macleod KG, Ritchie A, et al. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (''Iressa'').Br J Cancer, 2002,86:456-462.
9Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res,1999,5:909-916.
10Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst, 1997,89:341-343.
